Welcome to our website!

12-01-2016

What about the new medication, 

Entresto (sacubtril/valsartan):   

We are learning about this new medication, FDA approved for use in treatment of heart failure with reduced EF.  I have heard from 14 PPCM subject users of Entresto. 5 of those 14 have just begun and no new echo yet, so don't yet know response. Of the 9 remaining, 7 (78 %) had response of gain EF of 20 points or more; 1 had no change; 1 had to stop due to side-effects. Some of those 7 "improvers" had "plateaued" for some months, so that response is encouraging, seemingly an advantage over previous treatment.  You may want to discuss this with your cardiologist.


11-12-2016:

Clinical Obstetrics, Gynecology and Reproductive Medicine

Short Communication

Teamwork in diagnosing and treating peripartum cardiomyopathy

James D Fett*

Peripartum Cardiomyopathy Projects, 2331 Mt. Hood Ct. SE, Lacey, WA 98503, USA

Introduction

When the diagnosis of peripartum cardiomyopathy (PPCM) can be made very early in its course the systolic heart function will be better preserved [1]. When the echocardiographic left ventricular ejection fraction (LVEF) is better, recovery outcomes will also be better [2]. Earlier diagnosis depends upon earlier recognition of symptoms that may be very similar to normal term pregnancy symptoms. When all of those involved in the care of new mothers, including the subjects themselves, are aware of a possibility for the development of pregnancy- associated heart failure in someone who has previously had perfectly normal heart function, then earlier diagnosis can easily be confirmed by echocardiography.

PPCM is still one of the leading causes of maternal mortality [3-5]. Unrecognized, it progresses at variable rates into severe heart failure threatening the life of both mother and unborn child or neonate. While not a common condition, it is also not rare. In the USA, incidence varies from approximately 1 case per 1500 live births in those mothers with African heritage to 1 case per 3000 in mothers without African heritage. Delay in diagnosis may lead to maternal mortality, newborn fatality, or survival of a mother with chronic cardiomyopathy and varying severity of heart failure for the rest of her life. Nevertheless, PPCM is a form of dilated cardiomyopathy with the greatest potential for full recovery, particularly when diagnosed early and treated appropriately, following evidence-based guidelines [2,6].

How can an earlier diagnosis of PPCM be made?

Greater awareness is already having an impact, leading to improving outcomes. Increasing attention must be given to enhance this awareness among all subjects with pregnancy as well as all their medical caregivers, including birthing center personnel, obstetrical nurses and aides, primary care physicians, emergency room physicians, obstetricians and cardiologists.

A self-test for heart failure in pregnancy is available for quantification of common symptoms [7]. Scores of 5 and higher continue to be validated as indicating the need for carrying out additional testing, including serum B-type Natriuretic Peptide (BNP) and/or echocardiography. It is important to work quickly in this assessment because, once triggered, the PPCM process may move very rapidly; in which case the LVEF falls to levels that risk the subject’s susceptibility to ventricular tachyarrhythmias and sudden cardiac arrest. Once recognized, early treatment reverses the cardiomyopathic process and gives the greatest potential for avoiding those dangerous levels of systolic dysfunction, providing the greatest potential for subsequently returning to normal heart function.

What is the treatment of PPCM?

Evidence-based “Guidelines” for the initial treatment of heart failure with reduced LVEF include diuretics, beta-blockers (BB) and ACE- inhibitors or angiotensin receptor blockers (ACEI/ARB) in tolerable dosages as “Class I (“should use”) recommendations [6]. Usually, ACEI are started first followed by BB when there is hemodynamic stability; however, reverse order has been used and is also effective. The combination of ACEI + BB seems to have a synergistic effect that is beneficial.

We do not yet know if the new dual angiotensin receptor blocker (ARB) and neprilysin inhibitor (ARNI) will be more effective than an ACEI; but it does show promise of benefit for some [9]. We do know that newer intervention trials are needed to help those who currently are the most resistant to full recovery; namely, those who at diagnosis have LVEF < 0.30 and left ventricular end-diastolic diameter (LVEDD) 6 cm [2].

Thus far, inhibition of the lactating hormone, prolactin, with the use of bromocriptine has neutral or disappointing results; and continuation of breastfeeding has not been shown to be detrimental to recovery [2,10,11]. More work needs to be done on the prolactin theory of causation to be sure that findings on the mouse model can indeed translate to the human model, in which there may be more resistance to cleavage of normal prolactin into a cardiotoxic metabolite (genetically determined?) [11-13].

First priority is to initiate the recovery phase. The issue of safety for subsequent pregnancies can be considered later

It is helpful to indicate to the new mother that the safety of future pregnancies depends upon achieving full recovery of heart function. We now know that most women who experience full recovery are indeed able to safely have a subsequent pregnancy [8,14,15]. We are still learning about the risks for relapse of heart failure in subsequent pregnancies. This type of relapse is still a possibility in some of those

Correspondence to: James D. Fett, MD, Peripartum Cardiomyopathy Projects, 2331 Mt. Hood Ct. SE, Lacey, WA 98503, USA; Co-Director and Steering Committee, Peripartum Cardiomyopathy Network (PCN), IPAC =Investigations in Pregnancy-Associated Cardiomyopathy, (Principal Investigator and Co-Director, Dennis McNamara, MD), Tel: 360-438-5270; E-mail: [email protected]

Received: November 06, 2015; Accepted: December 07, 2015; Published: December 10, 2015

Clin Obstet Gynecol Reprod Med, 2015 doi: 10.15761/COGRM.1000127

Volume 1(4): 108-109

A new era

This is a new era for PPCM.
progress. Working together as a team we are now in a much better position to help every PPCM mother fully recover.

References

  1. Fett JD (2013) Earlier detection can help avoid many serious complications of peripartum cardiomyopathy. Future Cardiol 9: 809-816. [Crossref]

  2. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, et al. (2015) Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol 66: 905-914. [Crossref]

  3. James D Fett (2014) Peripartum cardiomyopathy: A puzzle closer to solution. World J Cardiol 6: 87-99. [Crossref]

  4. Elkayam U (2011) Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol 58: 659-670. [Crossref]

  5. Goland S, Modi K, Bitar F, Janmohamed M, Mirocha JM, et al. (2009) Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 15: 645- 650. [Crossref]

  1. Sabe MA, Jacob MS, Taylor DO (2015) A new class of drugs for systolic heart failure: The PARADIGM-HF study. Cleve Clin J Med 82: 693-701. [Crossref]

  2. Safirstein JG, Ro AS, Grandhi S, Wang L, Fett JD, et al. (2012) Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol 154: 27-31. [Crossref]

  3. Haghikia A, Podewski E, Libhaber E, Labidi S, Fischer D, et al. (2013) Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 108: 366. [Crossref]

  4. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, et al. (2012) Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485: 333-338. [Crossref]

  5. Piwnica D, Touraine P, Struman I, Tabruyn S, Bolbach G, et al. (2004) Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. Mol Endocrinol 18: 2522-2542. [Crossref]

  6. Fett JD, Fristoe KL, Welsh SN (2010) Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. Int J Gynaecol Obstet 109: 34-36. [Crossref]

  7. Elkayam U, Tummala PP, Rao K, Akhter MW, Karaalp IS, et al. (2001) Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 344: 1567-1571. [Crossref]

Fett JD (2015) Teamwork in diagnosing and treating peripartum cardiomyopathy

Copyright: ©2015 Fett JD. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Clin Obstet Gynecol Reprod Med, 2015 doi: 10.15761/COGRM.1000127

Volume 1(4): 108-109 

05-15-2016:

Another new study from IPAC:

 2016 May;4(5):380-8. doi: 10.1016/j.jchf.2016.01.004. Epub 2016 Mar 9.

Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study.

Abstract

OBJECTIVES: 

This study explored the association of vascular hormones with myocardial recovery and clinical outcomes in peripartum cardiomyopathy (PPCM).

BACKGROUND: 

PPCM is an uncommon disorder with unknown etiology. Angiogenic imbalance may contribute to its pathophysiology.

METHODS: 

In 98 women with newly diagnosed PPCM enrolled in the Investigation in Pregnancy Associated Cardiomyopathy study, serum was obtained at baseline for analysis of relaxin-2, prolactin, soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF). Left ventricular ejection fraction (LVEF) was assessed by echocardiography at baseline and 2, 6, and 12 months.

RESULTS: 

Mean age was 30 ± 6 years, with a baseline of LVEF 0.35 ± 0.09. Relaxin-2, prolactin, and sFlt1 were elevated in women presenting early post-partum, but decreased rapidly and were correlated inversely with time from delivery to presentation. In tertile analysis, higher relaxin-2 was associated with smaller left ventricular systolic diameter (p = 0.006) and higher LVEF at 2 months (p = 0.01). This was particularly evident in women presenting soon after delivery (p = 0.02). No relationship was evident for myocardial recovery and prolactin, sFlt1 or VEGF levels. sFlt1 levels were higher in women with higher New York Heart Association functional class (p = 0.01) and adverse clinical events (p = 0.004).

CONCLUSIONS: 

In women with newly diagnosed PPCM, higher relaxin-2 levels soon after delivery were associated with myocardial recovery at 2 months. In contrast, higher sFlt1 levels correlated with more severe symptoms and major adverse clinical events. Vascular mediators may contribute to the development of PPCM and influence subsequent myocardial recovery. (Investigation in Pregnancy Associate Cardiomyopathy [IPAC]; NCT01085955).

Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

KEYWORDS: 

cardiomyopathy; heart failure; hormones; pregnancy and post-partum

 2016 Jan 21;374(3):233-41. doi: 10.1056/NEJMoa1505517. Epub 2016 Jan 6.

 2016 Mar;9(3):e002683. doi: 10.1161/CIRCHEARTFAILURE.115.002683.

GNB3 C825T Polymorphism and Myocardial Recovery in Peripartum Cardiomyopathy: Results of the Multicenter Investigations of Pregnancy-Associated Cardiomyopathy Study.

Abstract

BACKGROUND: 

Black women are at greater risk for peripartum cardiomyopathy (PPCM). The guanine nucleotide-binding proteins β-3 subunit (GNB3) has a polymorphism C825T. The GNB3 TT genotype more prevalent in blacks is associated with poorer outcomes. We evaluated GNB3 genotype and myocardial recovery in PPCM.

METHODS AND RESULTS: 

A total of 97 women with PPCM were enrolled and genotyped for the GNB3 T/C polymorphism. Left ventricular ejection fraction (LVEF) was assessed by echocardiography at entry, 6 and 12 months postpartum. LVEF over time in subjects with the GNB3 TT genotype was compared with those with the C allele overall and in black and white subsets. The cohort was 30% black, age 30+6, LVEF 0.34+0.10 at entry 31+25 days postpartum. The % GNB3 genotype for TT/CT/CC=23/41/36 and differed markedly by race (blacks=52/38/10 versus whites=10/44/46, P<0.001). In subjects with the TT genotype, LVEF at entry was lower (TT=0.31+0.09; CT+CC=0.35+0.09, P=0.054) and this difference increased at 6 (TT=0.45+0.15; CT+CC=0.53+0.08, P=0.002) and 12 months (TT=0.45+0.15; CT+CC=0.56+0.07, P<0.001.). The difference in LVEF at 12 months by genotype was most pronounced in blacks (12 months LVEF for GNB3 TT=0.39+0.16; versus CT+CC=0.53+0.09, P=0.02) but evident in whites (TT=0.50++0.11; CT+CC=0.56+0.06, P=0.04).

CONCLUSIONS: 

The GNB3 TT genotype was associated with lower LVEF at 6 and 12 months in women with PPCM, and this was particularly evident in blacks. Racial differences in the prevalence and impact of GNB3 TT may contribute to poorer outcomes in black women with PPCM.

© 2016 American Heart Association, Inc.

KEYWORDS: 

cardiomyopathy; heart failure; peripartum period; polymorphism genetics; pregnancy


Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies.

Abstract

Background Peripartum cardiomyopathy shares some clinical features with idiopathic dilated cardiomyopathy, a disorder caused by mutations in more than 40 genes, including TTN, which encodes the sarcomere protein titin. Methods In 172 women with peripartum cardiomyopathy, we sequenced 43 genes with variants that have been associated with dilated cardiomyopathy. We compared the prevalence of different variant types (nonsense, frameshift, and splicing) in these women with the prevalence of such variants in persons with dilated cardiomyopathy and with population controls. Results We identified 26 distinct, rare truncating variants in eight genes among women with peripartum cardiomyopathy. The prevalence of truncating variants (26 in 172 [15%]) was significantly higher than that in a reference population of 60,706 persons (4.7%, P=1.3×10(-7)) but was similar to that in a cohort of patients with dilated cardiomyopathy (55 of 332 patients [17%], P=0.81). Two thirds of identified truncating variants were in TTN, as seen in 10% of the patients and in 1.4% of the reference population (P=2.7×10(-10)); almost all TTN variants were located in the titin A-band. Seven of the TTN truncating variants were previously reported in patients with idiopathic dilated cardiomyopathy. In a clinically well-characterized cohort of 83 women with peripartum cardiomyopathy, the presence of TTN truncating variants was significantly correlated with a lower ejection fraction at 1-year follow-up (P=0.005). Conclusions The distribution of truncating variants in a large series of women with peripartum cardiomyopathy was remarkably similar to that found in patients with idiopathic dilated cardiomyopathy. TTN truncating variants were the most prevalent genetic predisposition in each disorder. 


08-18-2015:  IPAC OUTCOME REPORT:

Clinical Outcomes for

Peripartum Cardiomyopathy

in North America

VOL. 66, NO. 8, 2015 ISSN 0735-1097/$36.00 http://dx.doi.org/10.1016/j.jacc.2015.06.1309

Results of the IPAC Study
(Investigations of Pregnancy-Associated Cardiomyopathy)

Dennis M. McNamara, MD, MS,* Uri Elkayam, MD,y Rami Alharethi, MD,z Julie Damp, MD,x Eileen Hsich, MD,k Gregory Ewald, MD,{ Kalgi Modi, MD,# Jeffrey D. Alexis, MD,** Gautam V. Ramani, MD,yy Marc J. Semigran, MD,zz Jennifer Haythe, MD,xx David W. Markham, MD,kk Josef Marek, MD,* John Gorcsan III, MD,* Wen-Chi Wu, PHD,{{ Yan Lin, PHD,{{ Indrani Halder, PHD,## Jessica Pisarcik, BSN,* Leslie T. Cooper, MD,*** James D. Fett, MD,*

for the IPAC Investigators

ABSTRACT

BACKGROUND Peripartum cardiomyopathy (PPCM) remains a major cause of maternal morbidity and mortality. 

OBJECTIVES This study sought to prospectively evaluate recovery of the left ventricular ejection fraction (LVEF) and clinical outcomes in the multicenter IPAC (Investigations of Pregnancy Associated Cardiomyopathy) study.

METHODS We enrolled and followed 100 women with PPCM through 1 year post-partum. The LVEF was assessed
by echocardiography at baseline and at 2, 6, and 12 months post-partum. Survival free from major cardiovascular events (death, transplantation, or left ventricular [LV] assist device) was determined. Predictors of outcome, particularly race, parameters of LV dysfunction (LVEF), and remodeling (left ventricular end-diastolic diameter [LVEDD]) at pre- sentation, were assessed by univariate and multivariate analyses.

RESULTS The cohort was 30% black, 65% white, 5% other; the mean patient age was 30 ` 6 years; and 88% were receiving beta-blockers and 81% angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. The LVEF at study entry was 0.35 ` 0.10, 0.51 ` 0.11 at 6 months, and 0.53 ` 0.10 at 12 months. By 1 year, 13% had experienced major events or had persistent severe cardiomyopathy with an LVEF <0.35, and 72% achieved an LVEF $0.50. An initial LVEF <0.30 (p 1⁄4 0.001), an LVEDD $6.0 cm (p

Having the privilege to serve as Co-Director and Steering Committee member, I promote learning about PPCM through IPAC (Investigations in Pregnancy Associated Cardiomyopathy), an NIH-sponsored study of PPCM by the Peripartum Cardiomyopathy Network (PCN) with 30 medical centers in North America.   Detailed information and location of centers can be found on the IPAC website (Dennis McNamara, MD, Co-Director and Principal Investigator, U Pitt Med Center):  http://www.peripartumcmnetwork.pitt.edu.

Contact locations are also shown on a separate page of this web-site.

Having first encountered PPCM in Haiti almost 30 years ago, I also continue to work with PPCM mothers in Haiti through Hospital Albert Schweitzer: http://www.hashaiti.org.

                                              --JD Fett, MD

(Shown below:  PPCM clinic in Haiti, 2002, where our PPCM Diagnosis & Treatment program has dramatically reduced mortality rates and increased recovery rates.   Thanks be to the Unlimited Divine Creator!)

image002


Link to IPAC:
  
Site Map